Gastric adenocarcinoma

This trial tests whether giving immunotherapy drugs before surgery can completely eliminate tumors in patients with a specific type of stomach or gastro-esophageal junction cancer that has a high number of genetic mutations. Participants will receive either one drug (zimberelimab…

This trial tests whether adding the immunotherapy drug toripalimab to two different chemotherapy regimens, given before surgery, can help people with locally advanced gastric adenocarcinoma. About 248 adults with HER2-negative stomach cancer will receive either docetaxel, oxalipl…

This pilot study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation therapy before surgery can help treat stomach cancer that can be surgically removed. The study includes 32 participants and primarily lo…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This phase III trial is testing whether adding radiotherapy to standard chemotherapy improves survival in patients with HER2 negative esophageal or gastric cancer that has spread to a few other spots in the body (oligometastatic). About 314 participants will receive either chemot…

This trial is testing whether adding an experimental immunotherapy (QL1706) to a standard chemotherapy regimen (DOS) before surgery can help people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if the combination can completely eliminate th…

Researchers are testing whether combining FLOT chemotherapy, trastuzumab and toripalimab before and after surgery helps people with HER2-positive stomach or esophagogastric junction cancer. The trial enrolls about 30 adults with locally advanced, operable tumors. Participants rec…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab first, followed by a combination of ramucirumab and paclitaxel, can shrink tumors and delay progression in people with advanced gastric or gastroesophageal junction adenocarcinoma. The study enrolls…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This early-phase trial is testing a new treatment called LB1908, which uses a patient's own immune cells (T-cells) that have been modified in the lab to recognize and attack cancer cells that have a protein called claudin 18.2 on their surface. The study includes up to 56 adults …

This study tests a drug called zolbetuximab that targets a protein (CLDN18.2) found in many stomach and gastroesophageal junction tumors. The drug is given alone or with chemotherapy and/or immunotherapy to see how well it controls tumor growth. The study includes 143 adults with…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests whether combining new drugs with or without chemotherapy can safely control advanced stomach, GEJ, or esophageal cancer. About 332 adults with inoperable or metastatic disease will receive different treatment combinations. The goal is to find more effective optio…

This study tests a drug called trastuzumab deruxtecan (T-DXd), alone or with chemotherapy and immunotherapy, in people with advanced HER2-positive stomach or esophageal cancer. The goal is to see if these combinations are safe and can shrink tumors. About 450 adults with cancer t…

This study follows about 257 adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already tried a trastuzumab-based treatment. Researchers will track how well the drug trastuzumab deruxtecan (T-DXd) works in everyday medical practice, including …

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This trial is testing whether giving a PD-1 immunotherapy drug after surgery can help people with a specific type of stomach cancer (MSI-H) live longer without the cancer coming back. Participants who had surgery to remove their stomach cancer will be randomly assigned to receive…

This early-phase study tests a new drug called BL-M05D1 in people with advanced or metastatic solid tumors (like stomach, pancreatic, or bile duct cancer) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug c…

This phase 2 trial is testing whether adding surufatinib (a targeted therapy that blocks blood vessel growth) to standard immunotherapy and chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment is given befor…

This phase 2 trial tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that has a specific genetic change (TP53 mutation) and was getting worse. The goal was to see if the combination could shrink…

This study tests an experimental drug called M9140 in people with advanced solid tumors (gastric, lung, or pancreatic cancer) that have a specific protein (CEACAM5). The drug is designed to deliver a toxin directly to cancer cells. About 250 adults will receive the drug alone or …

This trial tests whether combining an immunotherapy drug (tislelizumab) with standard chemotherapy and heated chemotherapy delivered directly into the abdomen can shrink tumors and improve survival in people with stomach cancer that has spread to the lining of the abdomen. The st…

This phase 2 trial is testing whether a combination of trifluridine/tipiracil (Lonsurf) plus oxaliplatin, with or without the immunotherapy nivolumab, can help people with advanced HER2-negative stomach, esophageal, or gastroesophageal junction cancer. The study compares these co…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This Phase 2 study tests a new drug, telisotuzumab adizutecan (ABBV-400), combined with standard chemotherapy and an immunotherapy drug for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. About 180 adults will recei…

This study tests whether adding zolbetuximab (a drug that targets a protein called Claudin 18.2 found on many stomach tumors) to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer without their cancer growing. About 500 adults…

This early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …

This early-phase trial tests whether a shorter course (2 weeks instead of 5) of chemoradiotherapy before standard chemotherapy and surgery is safe and effective for people with resectable stomach cancer. About 25 participants will receive the shortened radiation combined with che…

This study tests a surgical technique for early stomach cancer that combines a camera in the abdomen (laparoscopy) with a flexible tube down the throat (endoscopy). Doctors inject a fluorescent dye near the tumor to highlight the first lymph nodes that might contain cancer. If th…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This Phase 3 trial tests a new drug called AZD0901 against standard chemotherapy in 592 adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The drug targets a protein called CLDN18.2 found on some cancer cells. The study me…

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after stomach cancer surgery can help prevent the cancer from coming back. About 878 patients who had their stomach cancer completely removed will receive either toripalimab plus c…

This study tests whether adding tadalafil (a drug used for erectile dysfunction) to standard chemotherapy can help shrink stomach or gastroesophageal junction tumors before surgery. Ten adults with resectable cancer will receive tadalafil alone for two weeks, then combined with c…

This phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…

This early-phase trial tests whether adding an immune-boosting drug (aldesleukin) to standard chemotherapy and another immunotherapy (nivolumab) can help control stomach cancer that has spread to the lining of the abdomen. About 15 adults with this advanced cancer will receive th…

This study tests a new drug called AZD0901 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 33 participants will receive the drug, an…

This phase 2 trial is testing whether adding the drug neratinib to a standard combination of chemotherapy, trastuzumab, and pembrolizumab can shrink tumors in people with HER2-positive gastroesophageal cancers. The study includes 8 participants and aims to measure how many respon…

This phase 3 trial compares a newer targeted drug, trastuzumab deruxtecan, against a standard combination of two other drugs (ramucirumab and paclitaxel) in 490 adults with HER2-positive stomach or gastro-esophageal junction cancer that has worsened after initial treatment with t…

This phase 2 trial tests whether giving the immune checkpoint inhibitor IMC-001 before surgery can shrink tumors in people with resectable gastric, esophageal, or liver cancer. About 48 participants will receive two cycles of the drug, then undergo surgery. The main goal is to se…

This phase 3 study tests a new drug called IBI343 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has not responded to prior therapies. The trial includes 464 participants whose tumors have a specific marker (CLDN18.2) and lac…

This phase 2 trial is testing a five-drug combination for people with advanced esophageal, stomach, or gastroesophageal junction cancer that has worsened after initial treatment. The combination includes immune cells from healthy donors, two immunotherapy drugs, and two standard …

This study tests a new device called the Luso-Cor esophageal stent for closing leaks (fistulas) that can happen after weight-loss or cancer surgery on the stomach or esophagus. About 180 adults will be enrolled and their outcomes compared to those treated with standard stents or …

This Phase 3 trial tests whether adding zolbetuximab, an antibody that targets the Claudin 18.2 protein found on many stomach tumors, to standard chemotherapy can delay cancer progression in people with advanced stomach or gastroesophageal junction cancer. About 565 adults whose …

This study is testing whether a newer, less invasive type of stomach cancer surgery (using just one or a few small cuts) is as safe and effective as the standard approach. The trial involves 108 people with advanced stomach cancer who need their stomach partially removed. The mai…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This early-phase trial is testing the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen (intraperitoneal) for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. The study involves 27 pa…

This phase 2 trial tests whether a combination of lenvatinib, pembrolizumab, and chemotherapy (FLOT) can shrink stomach tumors before surgery and prevent recurrence afterward. It involves 43 adults with untreated, non-metastatic stomach cancer. The main goal is to see how many pa…

This phase 2 study tests two approaches for HER2-positive stomach or gastroesophageal junction cancer that hasn't spread. One group gets trastuzumab deruxtecan alone before surgery. Another group gets a combination of trastuzumab deruxtecan, capecitabine, and durvalumab both befo…

This study tests a procedure called PIPAC, which turns chemotherapy drugs into a mist and sprays them directly into the abdomen. It is for people with stomach cancer that has spread to the lining of the belly. The goal is to see if this approach is safe and can help control the d…

This phase 2 trial is testing a combination of three drugs—anlotinib, TQB2450, and the SOX chemotherapy regimen—as a first treatment for advanced stomach or gastroesophageal junction cancer that has low PD-L1 expression. The study involves 37 participants and aims to see how well…

This study tests a new antibody drug, S095029, combined with the immunotherapy pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The trial aims to see if the combination is safe and can shrink tumo…

This pilot trial tests whether using a patient's genetic profile to determine the dose of irinotecan (a chemotherapy drug) can improve outcomes for people with advanced stomach or esophageal cancer. The study combines chemotherapy before and after surgery, with the goal of increa…

This early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…

This phase 3 trial compares a new drug, MK-2870, against standard treatments for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has spread and not responded to prior therapies. About 450 participants will be randomly assigned to receive either …

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This study tests an experimental drug called LM-302 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has gotten worse after at least two prior therapies. The trial includes 387 adults whose tumors have a specific protein (CLDN1…

This phase II trial tests a combination of chemotherapy drugs for stomach cancer that has spread to the lining of the abdomen. About 40 adults will receive standard intravenous chemo plus paclitaxel infused directly into the abdomen. The goal is to see if this approach improves h…

This study tests whether adding the drugs camrelizumab and apatinib to standard chemotherapy (SOX) before surgery can help shrink tumors in people with locally advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before surgery. T…

This study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment be…

This early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction can…

This study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. Howe…

This phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…

This phase 2 study tests a drug called AK104, which helps the immune system attack cancer cells, in people with specific types of stomach or colorectal cancer. Participants receive the drug before and after surgery to see if it can completely eliminate the tumor. The trial involv…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (FLOT) before and after surgery helps people with resectable stomach or gastroesophageal junction cancer live longer without the cancer returning. About 957 participants receive either durv…

This study aimed to see if adding two immune-boosting drugs (zimberelimab and domvanalimab) to standard chemotherapy could help people with operable stomach or esophageal cancer. All participants would have received the treatment before and after surgery, then be followed for up …

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junc…

This phase 2 trial tests whether adding the immunotherapy drug serplulimab to standard FLOT chemotherapy can improve outcomes for people with stage III gastric cancer. About 138 participants will receive either the combo or chemo alone before surgery. The main goal is to see if t…

This study tests a drug called sacituzumab govitecan in 53 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug can shrink tumors. Researchers will also track how long any response lasts and how well the drug contro…

This study tests an experimental drug called AZD7789 in people with advanced lung, stomach, or gastroesophageal cancer that cannot be removed by surgery. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The trial aims to check if the drug …

This phase II trial tests a combination of three drugs—fruquintinib, sintilimab, and SOX (S-1 plus oxaliplatin)—as a pre-surgery treatment for people with stage IV gastric cancer that cannot be fully removed. The goal is to shrink the tumor enough to allow complete surgical remov…

This early-phase study tests a new drug called SI-B003 in 60 people with advanced solid tumors that have spread or come back. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side effect…

This phase 2 trial tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen (FOLFOX) improves outcomes for patients with resectable stomach or gastroesophageal junction cancer. 60 participants receive the three-drug combo before and after surge…

This early-stage trial is testing a new drug called ASKB589, which targets a protein (CLDN18.2) found on some stomach cancer cells. It is given together with standard chemotherapy and an immunotherapy drug. The study includes 62 people with advanced stomach or gastroesophageal ju…

This Phase 2 trial tests whether adding an experimental immunotherapy drug (SHR-8068) to a standard immunotherapy (adebrelimab) plus chemotherapy can shrink tumors better than standard treatment alone in people with advanced stomach or esophageal cancer. About 153 participants wi…

This study looks at whether a special type of CT scan (spectral CT) combined with a tumor marker (MSI status) can more accurately predict if stomach cancer has spread to nearby lymph nodes. Researchers will compare the CT results with the actual lymph node findings after surgery …

Researchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…

This study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…

This study compares two minimally invasive surgeries for cancer at the top of the stomach or where the stomach meets the esophagus: removing only the upper part (proximal gastrectomy) versus removing the entire stomach (total gastrectomy). The goal is to see which approach leads …

This phase II trial tests an enhanced recovery after surgery (ERAS) protocol in 52 people with stage 0 to IIIC gastric cancer who are having surgery. The goal is to see if this approach can reduce pain, nausea, and hospital stays while improving quality of life. Participants rece…

This study examines the extra costs of doing an upper endoscopy (stomach scope) at the same time as a routine colonoscopy for colon cancer screening. Researchers will also analyze the overall economic burden of treating stomach cancer. Data from 250 patients will be collected fro…

This study looks at how the immunotherapy drug nivolumab is used in routine care for adults with advanced cancers of the esophagus, gastroesophageal junction, or stomach. Researchers will analyze data from a Dutch cancer registry to see how long people live after starting nivolum…

This study looks at 80 patients with both locally advanced gastric cancer and high blood pressure. Researchers want to see if taking beta-blockers (a common blood pressure drug) alongside standard cancer treatment leads to better tumor shrinkage compared to other blood pressure d…

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The resea…

This study looks at whether using a small camera (laparoscopy) to see if stomach cancer has spread inside the belly can help doctors choose the best treatment. About 968 people with stage III stomach cancer will be randomly assigned to either standard care or care guided by this …

This study observes 208 adults in France with advanced or metastatic stomach, esophageal, or gastroesophageal junction cancer who are receiving nivolumab combined with chemotherapy as their first treatment. Researchers will track how long patients live and how their disease progr…

This study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…

This study looks back at 300 people with advanced stomach or gastroesophageal junction cancer to see how different treatments before and after surgery affect survival. The goal is to find out which treatment plans work best and whether tumor shrinkage after pre-surgery therapy pr…

This observational study collects blood and tumor tissue samples from people with gastroesophageal cancer to study genetic changes that may cause resistance to immunotherapy. It does not involve any treatment or experimental drugs. The goal is to identify new targets for future i…

This study examines whether men and women with gastric cancer receive different care in Germany. Researchers will analyze data from 75,000 patients treated between 2017 and 2021, looking at survival rates, complications, and treatment approaches. The goal is to identify gender-ba…